Flukonazol-Zdorovye forte kaps. 200 mg No. 4

Flukonazol-Zdorovye it is shown for treatment of such fungal infections at adults as:

• cryptococcal meningitis;
• coccidioidosis;
• invasive candidiases;
• candidiases of mucous membranes, including candidiasis of a stomatopharynx and candidiasis of a gullet, a kandiduriya, chronic candidiasis of skin and mucous membranes;
• chronic atrophic candidiasis of an oral cavity (the candidiasis caused by use of dentures) at inefficiency of hygiene of an oral cavity or local therapy.

Flukonazol-Zdorovye it is shown for prevention of such diseases at adults as:

• a recurrence of cryptococcal meningitis at patients with high risk of its development;
• a recurrence of candidiasis of a stomatopharynx or a gullet at patients with HIV with high risk of its development;
• prevention of candidosis infections at patients with a long neutropenia (for example, patients with malignant diseases have blood which receive chemotherapy or at patients at transplantation of haematopoietic stem cells).

Flukonazol-Zdorovye is applied to children since the birth to treatment of candidiases of mucous membranes (stomatopharynx candidiasis, gullet candidiasis), invasive candidiases, cryptococcal meningitis and to prevention of candidosis infections at patients with reduced immunity. Medicine can be applied as maintenance therapy to prevention of a recurrence of cryptococcal meningitis at children with high risk of its development.

before obtaining results of cultural and other laboratory researches; after obtaining results the antibacterial therapy should be corrected as appropriate.

Structure

Active ingredient: flukonazol;

1 capsule supports a flukonazol of 200 mg;

Excipients: lactose monohydrate, potato starch; povidone, calcium stearate the cover of the capsule supports the titan dioxide (E 171), gelatin, ink black (in case of drawing the trademark of the enterprise - ZT; contain Glaze shellac of 45% solution in ethanol, ferrous oxide black (E172), propylene glycol, ammonia the solution concentrated).

Contraindication

• Hypersensitivity to a flukonazol, to other azolny connections or to any of medicine excipients.
• Simultaneous application of a flukonazol and terfenadin to patients who receive flukonazol repeatedly in doses 400 mg/days and above (according to results of a research of interaction of repeated application).
• Simultaneous application of a flukonazol and other medicines extending an interval of QT and which are metabolized by means of CYP3A4 enzyme (for example a tsizaprida, an astemizola, Pimozidum, quinidine and erythromycin).

Route of administration

Dose of a flukonazol depends on a look and weight of a fungal infection.

In need of repeated use of medicine before disappearance of clinical and laboratory manifestations of activity of a fungal infection. The insufficient duration of treatment can lead to resuming of active infectious process.

intravenously by infusion. There is no need for change of a daily dose of medicine at change of a way of its application from oral on intravenous and vice versa.

Solution for infusions should be entered with a speed which is not exceeding 10 ml/min.

Feature of application

Pregnant

according to an observation research, there is an increased risk of spontaneous abortion at the women receiving flukonazol during І a pregnancy trimester. Reported about numerous congenital pathologies at newborns (including a bradyphrenia, an auricle dysplasia, excessive increase in a front fontanel, a hip curvature, a humero-ulnar synostosis) whose mothers accepted high doses of a flukonazol (400–800 mg/days) within at least three or more months for treatment of a coccidioidosis. Communication between application of a flukonazol and these cases is not defined.

Research on animals reproductive toxicity.

should not apply usual doses of a flukonazol and short-term courses of treatment flukonazoly during pregnancy, except for emergency.

should not apply high doses of a flukonazol and/or long courses of treatment flukonazoly during pregnancy, except for treatment of infections which threaten life.

Medicine children can apply

since the birth.

Drivers

Researches of influence of medicine on ability to steer motor transport or to work with other mechanisms.

Patients on a possibility of development of dizziness or spasms at use of medicine. At development of such symptoms it is not recommended to steer motor transport or to work with other mechanisms.

Overdose

received the message about overdose flukonazoly; at the same time reported about hallucinations and paranoid behavior.

At overdose symptomatic maintenance therapy and if necessary to wash out a stomach.

with urine; the artificial diuresis can accelerate medicine removal. The session of a hemodialysis lasting 3 hours reduces the level of a flukonazol in blood plasma approximately by 50%.

Side effects

Most often (> 1/10) was reported about such side reactions: headache, abdominal pain, diarrhea, nausea, vomiting, rash, increase in level of alaninaminotranspherase (ALT), aspartate aminotransferase (nuclear heating plant) and alkaline phosphatase of blood.

Interaction

Astemizol. Combined use of a flukonazol and astemizol can reduce clearance of an astemizol. The increase in concentration of an astemizol caused by it in blood plasma can lead to lengthening of an interval of QT and in rare instances – to Bouveret's ventricular disease of type "feasts". Simultaneous application of a flukonazol and astemizol is contraindicated.

Pimozidum and quinidine. Combined use of a flukonazol and Pimozidum or quinidine can lead to oppression of metabolism of Pimozidum or quinidine though the corresponding researches in vitro and in Vivo were not conducted. Increase in concentration of Pimozidum or quinidine in blood plasma can cause lengthening of an interval of QT and in rare instances lead to development of Bouveret's ventricular disease of type "feasts". Simultaneous application of a flukonazol and Pimozidum or quinidine contraindicated.

to Store

in original packing at a temperature not above 25 °C.

to Store

out of children's reach.

Expiration date - 5 years.